119 related articles for article (PubMed ID: 15982348)
1. CD34+ cell selection is required to assess HOXA9 expression levels in patients with myelodysplastic syndrome.
Heinrichs S; Berman JN; Ortiz TM; Kornblau SM; Neuberg DS; Estey EH; Look AT
Br J Haematol; 2005 Jul; 130(1):83-6. PubMed ID: 15982348
[TBL] [Abstract][Full Text] [Related]
2. Increased immature hematopoietic progenitor cells CD34+/CD38dim in myelodysplasia.
Monreal MB; Pardo ML; Pavlovsky MA; Fernandez I; Corrado CS; Giere I; Sapia S; Pavlovsky S
Cytometry B Clin Cytom; 2006 Mar; 70(2):63-70. PubMed ID: 16470534
[TBL] [Abstract][Full Text] [Related]
3. GATA-1 transcription factor is up-regulated in bone marrow hematopoietic progenitor CD34(+) and erythroid CD71(+) cells in myelodysplastic syndromes.
Maratheftis CI; Bolaraki PE; Voulgarelis M
Am J Hematol; 2007 Oct; 82(10):887-92. PubMed ID: 17570514
[TBL] [Abstract][Full Text] [Related]
4. Comparative analysis of hypermethylation of cell cycle control and DNA-mismatch repair genes in low-density and CD34+ bone marrow cells from patients with myelodysplastic syndrome.
Hofmann WK; Takeuchi S; Takeuchi N; Thiel E; Hoelzer D; Koeffler HP
Leuk Res; 2006 Nov; 30(11):1347-53. PubMed ID: 16682076
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the prognostic relevance of L-selectin and ICAM1 expression in myelodysplastic syndromes.
Buccisano F; Maurillo L; Tamburini A; Del Poeta G; Del Principe MI; Ammatuna E; Consalvo MI; Campagna S; Ottaviani L; Sarlo C; Renzi D; Faccia S; Fraboni D; Lo Coco F; Amadori S; Venditti A
Eur J Haematol; 2008 Feb; 80(2):107-14. PubMed ID: 18028430
[TBL] [Abstract][Full Text] [Related]
6. Over-expression of tumor necrosis factor-alpha in bone marrow biopsies from patients with myelodysplastic syndromes: relationship to anemia and prognosis.
Stifter G; Heiss S; Gastl G; Tzankov A; Stauder R
Eur J Haematol; 2005 Dec; 75(6):485-91. PubMed ID: 16313260
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of the Doppel protein in acute myeloid leukaemias and myelodysplastic syndromes.
Travaglino E; Comincini S; Benatti C; Azzalin A; Nano R; Rosti V; Ferretti L; Invernizzi R
Br J Haematol; 2005 Mar; 128(6):877-84. PubMed ID: 15755294
[TBL] [Abstract][Full Text] [Related]
8. Reduced number of circulating endothelial progenitors and HOXA9 expression in CD34+ cells of hypertensive patients.
Pirro M; Schillaci G; Menecali C; Bagaglia F; Paltriccia R; Vaudo G; Mannarino MR; Mannarino E
J Hypertens; 2007 Oct; 25(10):2093-9. PubMed ID: 17885552
[TBL] [Abstract][Full Text] [Related]
9. Maturation-associated immunophenotypic abnormalities in bone marrow B-lymphocytes in myelodysplastic syndromes.
Ribeiro E; Matarraz Sudón S; de Santiago M; Lima CS; Metze K; Giralt M; Saad ST; de Matos AO; Lorand-Metze I
Leuk Res; 2006 Jan; 30(1):9-16. PubMed ID: 16005514
[TBL] [Abstract][Full Text] [Related]
10. CD34/CD117 positivity in assessment of prognosis in children with myelodysplastic syndrome.
Tavil B; Cetin M; Tuncer M
Leuk Res; 2006 Feb; 30(2):222-4. PubMed ID: 16098587
[TBL] [Abstract][Full Text] [Related]
11. Advanced pediatric myelodysplastic syndromes: can immunophenotypic characterization of blast cells be a diagnostic and prognostic tool?
Veltroni M; Sainati L; Zecca M; Fenu S; Tridello G; Testi AM; Merlone AD; Buldini B; Leszl A; Lo Nigro L; Longoni D; Bernini G; Basso G;
Pediatr Blood Cancer; 2009 Mar; 52(3):357-63. PubMed ID: 19061215
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes.
De Smet D; Trullemans F; Jochmans K; Renmans W; Smet L; Heylen O; Bael AM; Schots R; Leus B; De Waele M
Am J Clin Pathol; 2012 Nov; 138(5):732-43. PubMed ID: 23086775
[TBL] [Abstract][Full Text] [Related]
13. Enforced expression of NUP98-HOXA9 in human CD34(+) cells enhances stem cell proliferation.
Chung KY; Morrone G; Schuringa JJ; Plasilova M; Shieh JH; Zhang Y; Zhou P; Moore MA
Cancer Res; 2006 Dec; 66(24):11781-91. PubMed ID: 17178874
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide DNA-mapping of CD34+ cells from patients with myelodysplastic syndrome using 500K SNP arrays identifies significant regions of deletion and uniparental disomy.
Nowak D; Nolte F; Mossner M; Nowak V; Baldus CD; Hopfer O; Noll S; Thiel E; Wagner F; Hofmann WK
Exp Hematol; 2009 Feb; 37(2):215-224. PubMed ID: 19135900
[TBL] [Abstract][Full Text] [Related]
15. NUP98 dysregulation in myeloid leukemogenesis.
Moore MA; Chung KY; Plasilova M; Schuringa JJ; Shieh JH; Zhou P; Morrone G
Ann N Y Acad Sci; 2007 Jun; 1106():114-42. PubMed ID: 17442773
[TBL] [Abstract][Full Text] [Related]
16. Impaired mitochondrial gene transcription in myelodysplastic syndromes and acute myeloid leukemia with myelodysplasia-related changes.
Schildgen V; Wulfert M; Gattermann N
Exp Hematol; 2011 Jun; 39(6):666-675.e1. PubMed ID: 21447369
[TBL] [Abstract][Full Text] [Related]
17. Transcriptosome and serum cytokine profiling of an atypical case of myelodysplastic syndrome with progression to acute myelogenous leukemia.
Mahadevan D; DiMento J; Croce KD; Riley C; George B; Fuchs D; Mathews T; Wilson C; Lobell M
Am J Hematol; 2006 Oct; 81(10):779-86. PubMed ID: 16838325
[TBL] [Abstract][Full Text] [Related]
18. A perforin/granzyme-positive MDS-derived T cell line, K2-MDS, induces apoptosis in CD34+ cells through the fractalkine-CX3CR1 system.
Morita Y; Matsuda M; Hanamoto H; Shimada T; Tatsumi Y; Maeda Y; Kanamaru A
Clin Immunol; 2004 Oct; 113(1):109-16. PubMed ID: 15380536
[TBL] [Abstract][Full Text] [Related]
19. Impaired generation of bone marrow CD34-derived dendritic cells with low peripheral blood subsets in patients with myelodysplastic syndrome.
Micheva I; Thanopoulou E; Michalopoulou S; Kakagianni T; Kouraklis-Symeonidis A; Symeonidis A; Zoumbos N
Br J Haematol; 2004 Sep; 126(6):806-14. PubMed ID: 15352984
[TBL] [Abstract][Full Text] [Related]
20. Telomerase activity in myelodysplastic syndromes.
Gürkan E; Tanriverdi K; Başlamişli F
Leuk Res; 2005 Oct; 29(10):1131-9. PubMed ID: 16111531
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
